kai5
16 Apr 2018
Increase in price Not sure what’s happening big volume with price increase
dave297
13 Apr 2018
Shorts I hope that those remaining are losing large amounts of dosh,as they caused us to, & will son decide to close their shorts resulting in a gathering of momentum in our recovery.Volumes have been higher than usual recently & ,as ever , there will be those who know what is going on behind the scenes - so lets hope there will be news soon to support our recovery.A takeover North of 160p would end the saga neatly !
d gaser
12 Apr 2018
AGM date plus risk assesment and info on J.V Found this in the new update and notice of AGM /Risk report, it concerns the Chinese J.V ,I'm not sure if it means the venture has now been written off ,or we have paid more than we expected. It can be found in the last chapter before the annual directors remuneration of key management personnel, which state's last year to Dec 2017 was £2.6m, but this year it will climb to £3.5m by December 2018 . Chippenham, UK - 12 April 2018: Vectura Group plc (LSE: VEC) ("Vectura", "the Group", "the Company"
announces that today it has released the following documents:· Report and Accounts for year ended 31 December 2017· Notice of Annual General Meeting ("AGM" 2018· Form of Proxy for the AGMunder RELATED-PARTY TRANSACTIONSAssociates In order to finalise the valuation process of the Group's Chinese associate, costs of £1.6m have been incurred comprising £0.6m for the cost of new equipment and a £1.0m waiver of a loan previously made to the associate. These contributions are considered arms-length related party transactions, necessary to finalise the valuation process.Question Doe's this mean ,we have given them the money and the company ? or have they taken control of the business with out putting any thing in ?,or doe's it mean, VEC have brought them out ,as they failed to meet their commitments ?, or some thing else? confused I am BE HAPPY DAVE See www.iii.co.uk/research/LSE:VEC/news/item/2746821/annual-report-and-accounts-2017-and-agm-2018?context=LSE:VEC
d gaser
11 Apr 2018
Invesco USA increase holding in VEC to 10.01 % I Missed this one , but it appears Invesco increased their holding from 9.96% to 10.01 % last month .As for the uncrossed trade, it was possible a short being closed ,BE HAPPYDAVE 3. Details of person subject to the notification obligation Name Invesco Ltd.City and country of registered office (if applicable)1555 Peachtree Street NE, Suite 1800, Atlanta, GA 30309 United StatesPosition of previous notification (if Applicable) 9.96% Resulting situation on the date on which threshold was crossed or reached66,481,559 or 10.01%BE HAPPY Dav
Matal
29 Mar 2018
Uncrossed trades Almost everyday someone is dumping a million (or over) in the 16.35 close auction at under bid price. Why? Another million today... creating an under bid uncrossed matched trade gone through in the auction. Someone is buying these up.... but who would want to sell below bid when they could get a higher price during the day?
raptor66
27 Mar 2018
Re: GSK to buy Novartis 36% of joint Ven... 'The company (VEC) said further partnerships would enable it to accelerate development of generic medicines for the US market'. 'It will also target more acquisitions to accelerate its growth'.[link] still think that Vectura merger with Verona Pharma (if their flagship drug phase iii proves pivotal) would be a good deal.[link]
dave297
27 Mar 2018
Re: GSK to buy Novartis 36% of joint Ventur... If they wanted to GSK could buy us for around £1bill which would be money well spent if it prevents a low cost generic in one of their areas of domination, apart from ending the royalty dispute & saving £9mill pa in royalties.They could sell of the parts they dont want for a few mill & left with want they want cheaply.Not HIK would be too chuft so they may have to buy us first.i do not give a monkeys I would just be very pleased to be out with 150p ( who wouldnt be ) even though I had expectations of £300p + when my SKP shares became Vec.
d gaser
27 Mar 2018
GSK to buy Novartis 36% of joint Venture ... GSK are not buying out Novartis, as it stands Novartis already own 36% of a joint venture between GSK and Novartis in their consumer healthcare division , But GSK have now agreed to buy that part of the J.V for USD13.0 billion, leaving Novartis to focus on other strategic priorities. That I would suggest means G.S.K won't be making a bid for VEC in the near future, but it could open up the possibility, of Novartis making an offer for VEC. Novartis as we all know own several products we have co-developed for them, and VEC last year alone received £17.3m in Royalties .Those products are now becoming big sellers across the world and means they will have to pay more in royalties as they grow, it would therefore, make sense, for Novartis to buy out VEC while the S/P is so low and take all the cash for them self’s.Novartis could then sell on any property rights they take hold off, such as G.S.K Advair, and the disputed Ellipta® rights, and then sell of the other products that Novartis don’t want, then add in the cash pile ,then any purchase of VEC by Novartis would pay for itself within 5 years or less ,especially at V.E.C present price BE HAPPYDAVE PDYH This is probably fiction, but it would be nice to see an offer soon for V.E.C .---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----- GSK TO BUY NOVARTIS 36% OF JOINT VENTURE IN HEALTHCARE DIVISSION • Price reflects an attractive value to Novartis • Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions • Sale of JV in a non-core segment in best long-term interests of Novartis shareholders • Completion expected in Q2 2018, subject to necessary approvals Basel, March 27, 2018 - Novartis announced today that it has entered into an agreement with GlaxoSmithKline plc (GSK) to divest its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for USD13.0 billion. The sale will enable Novartis to further focus on the development and growth of its core businesses. Vas Narasimhan, CEO of Novartis, said: "While our consumer healthcare joint venture with GSK is progressing well, the time is right for Novartis to divest a non-core asset at an attractive price. This will strengthen our ability to allocate capital to grow our core businesses, drive shareholder returns, and execute value creating bolt-on acquisitions as we continue to build the leading medicines company, powered by digital and data." The joint venture was formed in 2015 as part of Novartis' portfolio transformation, which comprised a three-part inter-conditional transaction with GSK, including the combination of the Novartis Over-the-Counter (OTC) business with the GSK consumer healthcare business into the existing JV. The consumer healthcare JV investment is accounted for in Novartis' financial reporting using the equity method of accounting, whereby the Company's share of the net income is reported as income from associated companies. BE HAPPY (Maybe Novartis will buy VEC out now ?)DAVE .
Matal
27 Mar 2018
GSK buy Novartis... Healthcare unit... which probably ends speculation that the would interested in VEC.
Ripley94
26 Mar 2018
Re: Topped up Bought that Friday slice back @ 79p bit cheaper then 13/03/18 top.
raptor66
26 Mar 2018
Re: Topped up It seems AXA Investment Managers have also increased their holding in VEC.[link]
Ripley94
23 Mar 2018
Re: Topped up Rns Director buys .. up 9%.. sliced Wednesdays top @ 81.25 ..quick 16 %.The more i practice .........
dave297
23 Mar 2018
Re: another 1,286,051free shares for the... I would love to know which KPIs they have achieved over the last year,although a halving of our SP is some achievement .Outrageous that they should be given so many free shares (apart from their very decent packages)after such an abysmal year.The only advantage to we mere PIs is that their interests are more aligned with ours & they now have even more to gain by achieving an exit at the highest price possible
Matal
23 Mar 2018
Re: another 1,286,051free shares for the Bod It makes absolutely no difference what the market sp is when the options are granted. Nil paid is stil nil paid! Contractual incentivised options and the start date timing of them are prior agreed at AGM's by shareholders. What they will actually be worth in 3 years time remains to be seen! As the blurb states... the performance targets are set out in the Directors Renumeration report in the accounts.
d gaser
23 Mar 2018
another 1,286,051free shares for the Bod How can they be granted such large Grants of free shares ,The S/P has headed south not North ,and what about the poor old share holders ,they don't even get an explanation as to why their shares have lost value since the mess of the take over of Sky pharma ,Both James ward Lilly and Andrew Derodra the Finance Director, have between them taken over two million free shares between them this week , to me they are just sticking two fingers up to the share holders .BE HAPPYDAVE today 1,286,051 shares are awarded at a price of NIL to James Ward-Lilley under the Company's Long Term Incentive Plan as a nil exercise price option. Vesting is subject to (i) stretching performance over 3 financial years commencing with the year of grant and (ii) continued service, and is normally 3 years after grant. Further details of the performance targets will be set out in the Directors' Remuneration Report included in the Company's Report and Accounts.
